Everyday Solutions, Inc.

Everyday Solutions, Inc. Appoints Tom Liebermann Executive Chairman Role

Everyday Solutions, Inc. Appoints Tom Liebermann Executive Chairman Role

July 29, 2010

Concord, MA USA – July 29, 2010 – Everyday Solutions, Inc., the leading provider of integrated solutions for managing School Transportation Information, announced today that Tom Liebermann has been appointed to the role of Executive Chairman of the Board. Mr. Liebermann will lead Everyday Solutions’ Board of Directors, help shape the strategic direction for the company and act as a sounding board for the executive management team on tactical and operational opportunities.

Flagship's Jim Matheson is Entrepreneur in Residence at Lawrence Berkeley National Laboratory

Flagship's Jim Matheson is Entrepreneur in Residence at Lawrence Berkeley National Laboratory

July 26, 2010

Berkeley Lab Gets Its Own Entrepreneur in Residence

JULY 26, 2010, by Julie Chao

VisEn Medical, Inc.

PerkinElmer to Acquire VisEn Medical, Inc.

PerkinElmer to Acquire VisEn Medical, Inc.

August 3, 2010

Global leader in human health and environmental health adds in vivo molecular imaging capabilities for enhancing preclinical research for more effective therapies

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI - News), a global leader focused on the health and safety of people and the environment, today announced that it has acquired VisEn Medical, Inc., an in vivo molecular imaging technology company based in Bedford, Massachusetts.

Black Duck Software, Inc.

Black Duck Wins Best Of Show At Corporate & Channel Computing Expo

Black Duck Wins Best Of Show At Corporate & Channel Computing Expo

June 29, 2006

The protexIP Software Compliance Management Solution Receives Honor for "Hottest New Idea"

Acceleron Pharma, Inc.

Acceleron Pharma Closes $30M Series B Financing

Acceleron Pharma Closes $30M Series B Financing

August 2, 2006

CAMBRIDGE, MA – August 2, 2006 - Acceleron Pharma, Inc., a biopharmaceutical company involved in the development of regenerative therapeutics, today announced that it secured a $30 million Series B financing. OrbiMed Advisors, the sole new investor, led the round with participation by all existing institutional investors including Advanced Technology Ventures, Flagship Ventures, Polaris Ventures, Sutter Hill Ventures and Venrock Associates. As part of this financing, Carl Gordon, Ph.D. of OrbiMed will join the Board of Directors.

VisEn Medical, Inc.

Olympus and VisEn Medical Sign Exclusive Japanese Distribution Agreement for Near Infrared Fluorescence Probes and Fluorescence Tomographic Imaging Systems

Olympus and VisEn Medical Sign Exclusive Japanese Distribution Agreement for Near Infrared Fluorescence Probes and Fluorescence Tomographic Imaging Systems

August 7, 2006

TOKYO & WOBURN, Mass.--(BUSINESS WIRE)--Aug. 7, 2006--Olympus Corporation (Olympus, President: Tsuyoshi Kikukawa) and VisEn Medical, Inc. (VisEn, CEO: Kirtland G. Poss), today announced that they have signed an exclusive Japanese distribution agreement covering VisEn's fluorescence molecular tomography(TM) (FMT(TM)) imaging systems and portfolio of in vivo near infrared fluorescence probes. Olympus will commence sales of the products from September 1, 2006.

Selventa

Genstruct Extends Collaboration in Cancer with GlaxoSmithKline

Genstruct Extends Collaboration in Cancer with GlaxoSmithKline

August 8, 2006

CAMBRIDGE, Mass., Aug. 8 /PRNewswire/ -- Genstruct Inc., a knowledge- driven discovery company using systems biology to increase the effectiveness of drug discovery and development, announced today that it will begin the second phase of a multi-phase agreement with GlaxoSmithKline plc (NYSE: GSK) (GSK), to jointly investigate compound mechanisms in oncology and to identify biomarkers for patient stratification and drug response.

BG Medicine, Inc.

Philips and BG Medicine Form Alliance for Molecular Medicine Research and Development

Philips and BG Medicine Form Alliance for Molecular Medicine Research and Development

August 11, 2006

Partners to Embark upon Joint Development of Molecular Imaging and Diagnostic Products

Mascoma Corporation

Mascoma Corporation Names Dr. Andrew Richard as CTO, Partners with Dartmouth for Expanded Cellulosic Ethanol Research

Mascoma Corporation Names Dr. Andrew Richard as CTO, Partners with Dartmouth for Expanded Cellulosic Ethanol Research

August 30, 2006

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 30, 2006--Mascoma Corporation, the leader in cellulosic biomass-to-ethanol development and production, today announced the appointment of Dr. Andrew Richard to the position of Chief Technology Officer. In this role Dr. Richard will apply his ethanol industry expertise and advance the company's technology and cellulosic ethanol processes through R&D and into the commercial market.

Adnexus Therapeutics

Adnexus Therapeutics Expands and Strengthens Senior Management Team

Adnexus Therapeutics Expands and Strengthens Senior Management Team

September 5, 2006

Experienced Drug Development Team to Drive Adnectin Product Pipeline and Corporate Development

9/5/2006 10:41:00 AM EST

Adnexus Therapeutics(TM) today announced expansion of its management team to advance corporate and pipeline development. Eric S. Furfine, Ph.D. holds the position of Senior Vice President of Research and Preclinical Development, Charles R. Carter is the company's Vice President, Finance, and Erin E. Lanciani assumes the role Vice President, Human Resources.